Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 380

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 380
---
 Developharma
completed the project. As a result of the completion, the Company issued 428,571 shares of common stock to Rivopharm and recorded additional research and development expense of $0.2 million.

In August 2023, contemporaneously with the closing of the Series C Offering, the Company entered into several amended and restated royalty participation
agreements (the “Amended and Restated Royalty Agreements”) with certain of its investors, co-founders, former directors, and executive officers, none of whom are Series C New Investors. No
consideration was received as part of the Amended and Restated Royalty Agreements. Pursuant to the Amended and Restated Royalty Agreements, the Company is obligated to pay royalties to all of the holders in an aggregate amount up to 2.75% on net
sales arising from LB-102 worldwide through December 31, 2035. Thereafter, the Company is obligated to pay royalties to such holders in an aggregate amount up to 3.25% in perpetuity. Future sales are
defined in these agreements as the gross payments received on total commercial sales of LB-102, whether by the Company or by any licensee of LB-102. As of
December 31, 2024, certain officers of the Company and their affiliates held 1.27% of the future royalties.

Prior to the closing of the Series C
Offering, three of the Company’s Board of Directors were replaced and the Company agreed to pay them a total of $0.2 million as part of their departure.

15. Subsequent Events

The Company evaluated subsequent
events through June 27, 2025, the date these financial statements were available to be issued, and has not identified any events requiring disclosure.

F-37

LB Pharmaceuticals Inc Condensed Balance Sheets (In thousands, except share and per share data) (Unaudited)

|                                                                                                                                                 |     | As of | June 30, 
     2025 |   |     |   | December 31, 
         2024 |   |
|:------------------------------------------------------------------------------------------------------------------------------------------------|:----|:------|---------:|:--|:----|:--|-------------:|:--|
| Assets                                                                                                                                          |     |       |          |   |     |   |              |   |
| Current assets                                                                                                                                  |     |       |          |   |     |   |              |   |
| Cash and cash equivalents                                                                                                                       |     |